🔍

ZIMLAB - Zim Laboratories

📊 NSE: ZIMLAB 🏢 Pharmaceuticals - Indian - Bulk Drugs & Formln 📅 Last Updated: 12/14/2025 15:23

📢 Recent Corporate Announcements

Zim Laboratories Allots 48,726 Equity Shares Under ESOS 2023

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 18 Apr 2026, 04:05 PM

Zim Laboratories Limited has approved the allotment of 48,726 equity shares to an eligible employee of its subsidiary company following the exercise of options under the ESOS 2023 scheme. The shares were issued at an exercise price of Rs. 77.40 per share, which includes a premium of Rs. 67.40. This move has marginally increased the company's paid-up equity share capital from Rs. 53.50 crore to Rs. 53.55 crore. The newly allotted shares will rank pari-passu with the existing equity shares of the company.

Allotment of 48,726 equity shares of face value Rs. 10 each under ESOS 2023
Exercise price fixed at Rs. 77.40 per share, including a premium of Rs. 67.40
Total paid-up capital increased to Rs. 53,54,90,370 consisting of 5,35,49,037 shares
The allotment represents a negligible equity dilution of approximately 0.09%

💡 No action is required as this is a routine corporate exercise with minimal impact on share value. Investors should focus on the company's core business performance and upcoming quarterly results.

ZIM Laboratories Promoter Confirms Zero Share Encumbrance for FY 2025-26

🟢 POSITIVE ⭐ 4/10

REGULATORY 📅 10 Apr 2026, 12:38 PM

Anwar Siraj Daud, the promoter of ZIM Laboratories Limited, has submitted a formal declaration under SEBI Takeover Regulations for the financial year ending March 31, 2026. The disclosure confirms that the promoter group and Persons Acting in Concert (PAC) did not create any direct or indirect encumbrance on their shareholding during the period. This routine filing provides transparency regarding the stability of the promoter's stake and ensures no shares were pledged as collateral. Such declarations are mandatory annual requirements to maintain corporate governance standards.

Promoter Anwar Siraj Daud confirms zero encumbrance of shares for the FY ended March 31, 2026.
Compliance submitted under Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
The declaration covers both the individual promoter and all Persons Acting in Concert (PAC).
Confirms that no shares were pledged or used as collateral for loans during the financial year.

💡 Investors should view this as a positive sign of promoter stability and financial health. No immediate action is required as this is a routine regulatory confirmation of an unencumbered stake.

ZIMLAB Increases Stake in ZIMTAS Pty Ltd to 99.96% via Rs 89.45 Lakh Investment

🟢 POSITIVE ⭐ 6/10

M&A 📅 09 Apr 2026, 03:06 PM

Zim Laboratories Limited (ZIMLAB) has announced an investment of Rs. 89,45,100 (approximately AUD 1,35,000) in the equity shares of ZIMTAS Pty Ltd. This transaction significantly increases ZIMLAB's total shareholding in the Australian entity to 99.96%. The investment is part of a larger board-approved outlay of up to Rs. 2.00 crores for this purpose. This move effectively makes ZIMTAS a wholly-owned subsidiary, allowing for better operational control and integration in international markets.

Invested Rs. 89,45,100 (AUD 1,35,000) in ZIMTAS Pty Ltd equity shares
Increased total shareholding in ZIMTAS Pty Ltd to 99.96% from previous levels
The investment is within the pre-approved limit of Rs. 2.00 crores
Strategic consolidation of the company's presence in the Australian pharmaceutical market

💡 Investors should monitor how this consolidation in the Australian market contributes to the company's export revenue and overall margins. No immediate action is required, but the stock remains a watch for growth in international markets.

Zim Laboratories Submits SEBI Regulation 74(5) Compliance Certificate for Q4 FY26

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 08 Apr 2026, 03:53 PM

Zim Laboratories Limited has filed its quarterly compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the period ended March 31, 2026. The certificate, issued by MUFG Intime India Private Limited, confirms that securities received for dematerialization were processed and listed on the stock exchanges. It also verifies that physical security certificates were mutilated and cancelled after due verification by the depository participant. This is a standard procedural filing required to maintain the integrity of the company's share registry.

Compliance certificate submitted for the quarter ended March 31, 2026
Issued by Registrar and Transfer Agent MUFG Intime India Private Limited
Confirms dematerialization requests were accepted or rejected within prescribed timelines
Verification of mutilation and cancellation of physical certificates completed
Ensures that the name of depositories has been substituted in the register of members

💡 No action is required as this is a routine regulatory filing confirming administrative compliance regarding share dematerialization.

Zim Laboratories Appoints Grant Thornton Bharat LLP as Internal Auditor for 3 Years

🟢 POSITIVE ⭐ 6/10

MANAGEMENT 📅 30 Mar 2026, 06:51 PM

Zim Laboratories Limited has appointed Grant Thornton Bharat LLP as its Internal Auditor for a three-year tenure starting from FY 2026-27. The appointment, approved by the Board on March 30, 2026, will cover the period through FY 2028-29. Engaging a globally recognized professional services firm like Grant Thornton is a strategic move to enhance internal control systems and corporate governance. This transition reflects the company's focus on maintaining high standards of financial oversight and regulatory compliance.

Appointment of Grant Thornton Bharat LLP as Internal Auditor for a fixed term of 3 years.
The audit tenure spans from Financial Year 2026-27 to Financial Year 2028-29.
The decision was finalized during a Board meeting held on March 30, 2026, which concluded at 04:10 p.m.
The appointment is made in accordance with Section 138 of the Companies Act, 2013.

💡 Investors should view this as a positive step toward strengthening corporate governance and internal risk management. No immediate action is required, but the move enhances the long-term credibility of the company's financial reporting.

Zim Laboratories Announces Trading Window Closure from April 1, 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 27 Mar 2026, 06:38 PM

Zim Laboratories Limited has informed the exchanges that its trading window for dealing in company securities will be closed starting April 1, 2026. This move is a standard compliance measure under SEBI (Prohibition of Insider Trading) Regulations, 2015, ahead of the company's financial results. The window will remain closed for all designated persons and their immediate relatives until 48 hours after the declaration of the financial results for the quarter and year ended March 31, 2026. This is a routine procedure to prevent any potential insider trading before sensitive financial data is made public.

Trading window closure effective from Wednesday, April 1, 2026
Closure applies to all Designated Persons and their immediate relatives
Window to reopen 48 hours after the announcement of Q4 and FY26 financial results

💡 No action is required as this is a routine regulatory filing. Investors should look out for the upcoming announcement of the board meeting date where financial results will be approved.

ZIM Laboratories Constitutes Advisory Board with Industry Veterans for Strategic Growth

🟢 POSITIVE ⭐ 6/10

MANAGEMENT 📅 17 Mar 2026, 07:36 PM

ZIM Laboratories has established a three-member Advisory Board to provide strategic guidance on business development and long-term growth. The board is chaired by Mr. Annaswamy Vaidheesh, former MD of GSK Pharmaceuticals, who brings nearly 40 years of healthcare leadership experience. Other members include Mr. Gautam Saigal, a private equity veteran with 35 years of experience, and Mr. Girdhar Balwani, who has 40 years of pharmaceutical experience across the Asia-Pacific region. This move is designed to strengthen the company's market expansion, brand strategy, and governance framework.

Appointed Mr. Annaswamy Vaidheesh, former MD of GSK Pharmaceuticals and VP South Asia, as Chairman of the Advisory Board.
Included Mr. Gautam Saigal, with 35+ years in private equity and investment banking, to advise on financial and strategic matters.
Included Mr. Girdhar Balwani, with 40+ years of pharma experience including roles as MD of UCB Pharma and Menarini.
The board will focus on long-term vision, market expansion, new business lines, and organizational structure.
The Advisory Board serves a purely advisory role with no legal, fiduciary, or executive powers over the company.

💡 Investors should view this as a positive step toward professionalizing the company's strategic roadmap and leveraging deep industry expertise for global expansion. Monitor for upcoming strategic shifts or new business lines that may result from this high-level advisory input.

Zim Laboratories to Meet Everflow Partners on March 20, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 16 Mar 2026, 05:10 PM

Zim Laboratories Limited has scheduled a virtual one-to-one meeting with Everflow Partners on March 20, 2026. The disclosure was made under Regulation 30 of the SEBI (LODR) Regulations, 2015, which governs material events. The company has clarified that no unpublished price sensitive information (UPSI) will be shared during this interaction. This is a routine engagement between the company management and institutional analysts.

Virtual one-to-one meeting scheduled for Friday, March 20, 2026.
Interaction is specifically with Everflow Partners.
Company confirms that no Unpublished Price Sensitive Information (UPSI) will be shared.
Disclosure filed in compliance with SEBI (LODR) Regulations, 2015.

💡 No immediate action is required as this is a routine investor relations activity. Investors may monitor for any post-meeting transcripts or presentations that might be uploaded to the exchanges for further insights.

Zim Laboratories Allots 47.64 Lakh Shares to Florintree Trinex LLP, Raising ₹35 Crore

🟢 POSITIVE ⭐ 8/10

FUNDRAISE 📅 13 Mar 2026, 02:30 PM

Zim Laboratories has successfully completed the allotment of 47,64,497 equity shares to Florintree Trinex LLP on a preferential basis. The shares were issued at a price of ₹73.46 each, resulting in a total capital infusion of approximately ₹35 crore. This allotment increases the company's paid-up equity share capital from ₹48.74 crore to ₹53.50 crore. Post-allotment, Florintree Trinex LLP holds an 8.91% stake in the company, marking the entry of a significant non-promoter investor.

Allotted 47,64,497 equity shares at an issue price of ₹73.46 per share
Total fundraise aggregates to approximately ₹34.99 crore from a single investor
Paid-up equity capital expanded from ₹48.74 crore to ₹53.50 crore
Investor Florintree Trinex LLP now holds an 8.91% stake in the company
Issue price includes a premium of ₹63.46 per share over the face value of ₹10

💡 The capital infusion and entry of a significant institutional-style investor are positive signals for the company's growth prospects. Investors should monitor the company's upcoming quarterly results to see how this capital is deployed for expansion or debt reduction.

Zim Laboratories Completes Closure of Step-down Subsidiary ZIM DMCC in Dubai

🟡 NEUTRAL ⭐ 4/10

OTHER 📅 23 Feb 2026, 07:00 PM

Zim Laboratories Limited has finalized the dissolution of its step-down subsidiary, ZIM Laboratories Middle East DMCC, effective February 23, 2026. The closure was formally approved by the Dubai Multi Commodities Centre Authority (DMCC Authority) following an initial board approval dated August 7, 2025. This move appears to be a part of the company's internal restructuring or streamlining of its international operations. The financial impact of this closure was not disclosed in the current filing.

Formal dissolution of ZIM Laboratories Middle East DMCC effective February 23, 2026
Closure approved by the Dubai Multi Commodities Centre Authority (DMCC Authority)
Follows the initial Board of Directors' approval granted on August 7, 2025
The entity was a step-down subsidiary of Zim Laboratories Limited

💡 Investors should view this as a routine corporate restructuring event. It is advisable to monitor upcoming quarterly results to see if this closure results in operational cost savings or reflects a change in the company's Middle East strategy.

Zim Laboratories Receives Credit Rating Reaffirmation for Rs 166.23 Cr Bank Facilities

🟡 NEUTRAL ⭐ 4/10

ROUTINE 📅 17 Feb 2026, 07:27 PM

ACUITE Ratings & Research Limited has reaffirmed the credit ratings for Zim Laboratories Limited's bank facilities totaling Rs 166.23 crores. The long-term rating for Rs 150.23 crores of facilities is maintained at 'ACUITE BBB' with a 'Stable' outlook. Additionally, the short-term rating for Rs 16.00 crores of facilities has been reaffirmed at 'ACUITE A3+'. This reaffirmation indicates a stable credit profile and consistent debt-servicing capability for the pharmaceutical company.

ACUITE Ratings reaffirmed the long-term rating at 'ACUITE BBB' with a 'Stable' outlook for Rs 150.23 crores.
The short-term rating was reaffirmed at 'ACUITE A3+' for facilities worth Rs 16.00 crores.
Total bank facilities covered under this rating exercise amount to Rs 166.23 crores.
The reaffirmation suggests the company's credit profile remains consistent with previous assessments.

💡 Investors should view this as a sign of financial stability, as the company maintains its creditworthiness. No immediate action is required, but continue to monitor for any future rating upgrades which could lower borrowing costs.

Zim Laboratories Q3 FY26 Revenue at INR 1,087 Mn; EU-GMP Audit Slated for H1 FY27

🔵 WATCH ⭐ 7/10

EARNINGS 📅 17 Feb 2026, 06:05 PM

Zim Laboratories reported a total operating income of INR 1,087 million for Q3 FY26, showing steady sequential improvement and a 23.2% YoY growth in exports. The company's EBITDA stood at INR 145 million with a margin of 13.4%, while Profit After Tax reached INR 44 million. A critical focus remains on the EU-GMP remediation process, with a regulatory audit expected in H1 FY27 to unlock high-value regulated markets. Additionally, the company raised INR 35 crores via a preferential issue to fund capacity expansion and regulatory compliance.

Total operating income reached INR 1,087 million in Q3 FY26, driven by strong export traction.
Export revenue grew 23.2% YoY to INR 906 million, contributing 88% of total operating income.
Innovative NIP and OTF product segments contributed INR 132 million, representing 12.2% of revenue.
Completed a preferential issue of INR 35 crores for pancreatin block expansion and CAPA implementation.
EU-GMP remediation audit tentatively scheduled for H1 FY27 (June-July 2026) to address previous non-compliance.

💡 Investors should closely track the outcome of the EU-GMP audit in early FY27, as successful certification is the key catalyst for launching high-margin products in Europe. While the base export business is growing, the stock's re-rating depends on clearing regulatory hurdles and scaling the innovative NIP portfolio.

ZIM Laboratories Shareholders Approve Preferential Issue of Equity Shares

🟢 POSITIVE ⭐ 8/10

FUNDRAISE 📅 16 Feb 2026, 04:17 PM

Zim Laboratories Limited held an Extraordinary General Meeting on February 16, 2026, where shareholders approved a special resolution for the issuance of equity shares via a preferential issue on a private placement basis. The resolution was passed with an overwhelming majority, receiving 99.99% of the total votes in favor. A total of 30.74 million votes were polled, representing approximately 63.07% of the company's total outstanding shares. This approval paves the way for the company to raise capital for its strategic initiatives.

Shareholders approved the issuance of equity shares through a preferential issue on a private placement basis via a special resolution.
The resolution received 99.9896% votes in favor (30,734,942 votes) and only 0.0104% against.
Total voter turnout represented 63.07% of the total 48,735,814 outstanding shares.
Promoter group participation was 100%, with all 16,207,980 promoter shares voting in favor of the resolution.
Public non-institutional shareholders showed strong support with 99.978% of their polled votes in favor.

💡 Investors should monitor subsequent filings for details on the issue price and the specific allottees to evaluate the impact of equity dilution. The strong shareholder mandate indicates high confidence in the company's fundraising and growth strategy.

Zim Laboratories Conducts EGM for Equity Issuance via Preferential Issue

🟢 POSITIVE ⭐ 7/10

FUNDRAISE 📅 16 Feb 2026, 03:23 PM

Zim Laboratories Limited held its first Extraordinary General Meeting (EGM) for FY 2025-26 on February 16, 2026, to seek shareholder approval for a preferential issue of equity shares. The meeting, attended by 42 members via video conferencing, focused on a special resolution for private placement of equity. Chairman Dr. Anwar Siraj Daud addressed the shareholders regarding the proposed capital infusion and provided general business updates. The final voting results are pending the scrutinizer's report and will be disclosed to the exchanges shortly.

Proposed a special resolution for the issuance of equity shares via preferential issue on a private placement basis.
The EGM was conducted on February 16, 2026, with 42 shareholders participating through video conferencing.
Chairman Dr. Anwar Siraj Daud provided updates on the company's strategic direction and the rationale for the fundraise.
Voting was facilitated through remote e-voting and an electronic system during the meeting, with results to be announced within statutory timelines.
The meeting was attended by key management personnel, including the CFO, Company Secretary, and representatives from Deloitte Haskins & Sells LLP.

💡 Investors should monitor the upcoming disclosure of the voting results and specific details regarding the pricing and allottees of the preferential issue. This capital raise is a significant event that could support future expansion or debt reduction.

Zim Laboratories Releases Q3 & 9M FY26 Earnings Call Audio Recording

🟡 NEUTRAL ⭐ 3/10

EARNINGS 📅 13 Feb 2026, 05:32 PM

Zim Laboratories Limited has made the audio recording of its Q3 and 9M FY26 earnings conference call available to the public. The call, held on February 13, 2026, discusses the company's financial and operational performance for the quarter and nine-month period ending December 31, 2025. This disclosure is a routine regulatory requirement under SEBI (LODR) Regulations, 2015, aimed at maintaining transparency with shareholders. Investors can access the recording through the link provided on the company's official website.

Audio recording of Q3 & 9M FY26 earnings conference call is now accessible via the company's website.
The disclosure is made in compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The recording provides management commentary on the financial results for the period ending December 31, 2025.
The filing ensures all investors have equal access to the information shared during the institutional investor meet.

💡 Investors should listen to the recording to understand management's outlook on growth and margins. No immediate trading action is required based on this routine compliance filing.

View All ZIMLAB Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Total operating income for Q2 FY26 was INR 887 million, a 23.6% sequential increase. The Pharmaceutical segment contributed 83% of revenue (INR 732 million), growing 30.7% QoQ. The Nutraceutical segment contributed 17% (INR 155 million), but faced a YoY decline due to the deferment of institutional orders and softer domestic demand (INR 38 million vs INR 50 million in Q1).

Geographic Revenue Split

Exports are the primary driver, accounting for 83% of total revenue (INR 728 million in Q2 FY26), reflecting a 21% sequential improvement. Domestic business contributed approximately 17% (INR 127 million), remaining broadly stable compared to previous quarters.

Profitability Margins

Profitability showed sequential improvement with a net loss reduction from INR 19 million in Q1 FY26 to INR 4 million in Q2 FY26. This was driven by a better product mix and operational efficiencies. Operating profit margin for FY24 was 12.04%, down from 14.33% in FY23 due to higher employee costs.

EBITDA Margin

EBITDA margin for Q2 FY26 stood at 8.8%, an improvement from 7.9% in Q1 FY26. Management expects a significant jump in EBITDA during H2 FY26 to align with FY25 levels, as historically 60% of business occurs in the second half of the fiscal year.

Capital Expenditure

Total planned debt-funded capex is INR 60.42 crore as of June 30, 2025. This includes INR 40.87 crore from external debt and INR 21.53 crore from internal accruals. Specific projects include a new Tamsulosin and Dutasteride facility and the relocation of the Cephalosporin unit to meet EU-GMP standards.

Credit Rating & Borrowing

The company maintains an 'Adequate' liquidity position with ratings reaffirmed by Acuité. Borrowing includes a planned INR 40.87 crore for capex. Interest costs are a factor in the financial risk profile, which moderated in FY24 due to higher debt levels for working capital and capex.

⚙️ Operational Drivers

Raw Materials

Specific chemical names and their exact percentage of total cost are not disclosed in the available documents; however, the company produces Cephalosporin, Tamsulosin, and Dutasteride formulations.

Import Sources

The company sources raw materials both internationally and from domestic suppliers within India to ensure business continuity and mitigate geopolitical risks.

Capacity Expansion

Planned expansion includes a new manufacturing facility for Tamsulosin and Dutasteride and the relocation of the Cephalosporin unit to comply with EU-GMP and WHO-GMP standards. Capex of INR 5-7 crore is also allocated for completing balance projects and INR 5 crore for CAPA implementation.

Raw Material Costs

Raw material costs are managed through a strategy of diversifying geographic presence and establishing alternative domestic sources to reduce dependence on single regions and mitigate price volatility.

Manufacturing Efficiency

Efficiency is being driven by a shift toward more digitized operations and a focus on high-margin New Innovative Products (NIP) and Oral Thin Films (OTF).

Logistics & Distribution

Distribution is global, covering 50+ countries including Asia, Africa, MENA, Latin America, and the EU. Exports account for 83% of revenue, making logistics a critical component of the cost structure.

📈 Strategic Growth

Expected Growth Rate

Growth Strategy

Growth will be achieved by completing EU-GMP remediation to unlock regulated markets, expanding the New Innovative Products (NIP) and Oral Thin Films (OTF) portfolio, and executing a robust order book in H2 FY26. The company is also pursuing contract manufacturing at alternate sites for 'Star product 1' to bypass current regulatory hurdles.

Products & Services

Small formulation dosages, sustained and controlled-release pellets, Oral Thin Films (OTF), New Innovative Products (NIP), Tamsulosin, Dutasteride, and Cephalosporin formulations.

Brand Portfolio

ZIM Laboratories, ZIM Health Technologies, ZIM Thinorals.

New Products/Services

New Innovative Products (NIP) and Oral Thin Films (OTF) contributed INR 81 million in Q2 FY26. Combined with licensing income (INR 29 million), these segments represent 19% of total operating income.

Market Expansion

Targeting high-potential developed markets in FY26, with recent investments in subsidiaries like ZIMTAS PTY LTD (Australia) and SIA ZIM Laboratories (Latvia) to strengthen local presence.

Market Share & Ranking

The company holds a 3 Star Export House Status from the Ministry of Commerce & Industry, India.

Strategic Alliances

The company uses strategic partnerships and local offices in 50+ countries; specific partner names for JVs are not disclosed.

🌍 External Factors

Industry Trends

The pharmaceutical industry is evolving toward stricter regulatory standards (EU-GMP/WHO-GMP) and innovative drug delivery systems like Oral Thin Films. ZIM is positioning itself as an innovation-led player to capture higher margins in developed markets.

Competitive Landscape

Faces intense competition from global generic players and local manufacturers in Pharmerging markets, leading to pricing pressures.

Competitive Moat

Moat is built on specialized R&D in drug delivery (OTF/NIP) and a 30-year track record in complex export markets. Sustainability depends on successfully regaining EU-GMP certification to monetize its patent/MA portfolio.

Macro Economic Sensitivity

Highly sensitive to global economic conditions and USD currency availability in 'Rest of World' (ROW) markets, which impacted the Nutra segment's ability to receive advance payments.

Consumer Behavior

Increased sensitivity toward product performance and a shift toward innovative dosage forms (sustained release/OTF) in both Pharma and Nutra segments.

Geopolitical Risks

Exposure to political instability and trade restrictions in 50+ countries. Mitigation involves geographic diversification and sourcing alternative raw materials domestically.

⚖️ Regulatory & Governance

Industry Regulations

Operations are heavily impacted by EU-GMP (European Union Good Manufacturing Practices) suspension, which has delayed the innovative-led segment. Compliance with WHO-GMP and DGFT (3 Star Export House) standards is also required.

⚠️ Risk Analysis

Key Uncertainties

The primary uncertainty is the timeline for EU-GMP remediation; failure to reinstate clearances will continue to stall growth in high-margin regulated markets.

Geographic Concentration Risk

83% of revenue is concentrated in export markets, with significant exposure to Pharmerging regions and the Middle East.

Third Party Dependencies

Dependency on a single customer for 14-15% of revenue and reliance on institutional orders for the Nutraceutical segment.

Technology Obsolescence Risk

The company is mitigating technology risks by investing 9.7% of revenue into R&D and shifting toward digitized manufacturing processes.

Credit & Counterparty Risk

Receivables risk is highlighted by the deterioration of the working capital cycle to 125 days and delays in receiving letters of credit from ROW customers.